in relation to biotechs in its position its small dilution. To say they are a 25 million market cap with 7.4 million cash with a runway all the way through to phase 2 and will be the only drug in the world come phase 2 to:
”We are thrilled to have completed the GLP studies,which have confirmed a favourable safety profile for NYR-BI03, giving us confidence that itwill transition well into human studies.”
We will have 5 cohorts come human studies and we will know after 10 days just like AGN early on safety leading us into Walter Reed and IND. That 3 million is minimal dilution.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)